Leap therapeutics announces initiation of randomized controlled part b of the defiance study of dkn-01 in colorectal cancer patients

Cambridge, mass., july 12, 2023 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer (crc) in its defiance study, it has initiated the 130 patient randomized controlled part b of the phase 2 study.
LPTX Ratings Summary
LPTX Quant Ranking